Immune-Modified Response Evaluation Criteria In Solid Tumors (imRECIST): Refining Guidelines to Assess the Clinical Benefit of Cancer Immunotherapy

Genitourinary CancerSkin Cancer
Do you want to read an article? Please log in or register.